|
37 |
기타암 |
Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 update
|
2023-09-19 |
33 |
|
36 |
기타암 |
Tyrosine kinase inhibitor toxicities: A society of gynecologic oncology review and recommendations
|
2023-09-19 |
12 |
|
35 |
자궁경부암 |
Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994 / JCO
|
2023-09-19 |
19 |
|
34 |
자궁경부암 |
Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study
|
2023-09-19 |
8 |
|
33 |
자궁체부암 |
Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients – An international pooled analysis of three ESGO accredited centres
|
2023-09-19 |
25 |
|
32 |
자궁체부암 |
Intrauterine manipulator during hysterectomy for endometrial cancer: a systematic review and meta-analysis of oncologic outcomes.
|
2023-09-19 |
15 |
|
31 |
자궁체부암 |
Survival outcomes of robotic-assisted laparoscopy versus conventional laparoscopy and laparotomy for endometrial cancer: A systematic review and meta-analysis
|
2023-09-19 |
14 |
|
30 |
난소암 |
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial
|
2023-09-19 |
9 |
|
29 |
난소암 |
Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01)
|
2023-09-19 |
14 |
|
28 |
자궁경부암 |
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo- controlled, phase 3 trial
|
2023-06-29 |
76 |
